Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$153.49 USD

153.49
4,070,437

+3.73 (2.49%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $144.75 -8.74 (-5.69%) 4:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AbbVie (ABBV) Gets Nod in EU for Lymphoma Drug's Expanded Use

by Zacks Equity Research

AbbVie's (ABBV) Tepkinly gets conditional approval in the EU to treat third-line patients with relapsed or refractory follicular lymphoma as a second indication.

Should Vanguard S&P Mid-Cap 400 ETF (IVOO) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IVOO

Mirum (MIRM) Banks on Livmarli, Overdependence a Concern

by Zacks Equity Research

Mirum's (MIRM) lead drug, Livmarli, continues to generate steady sales. The recent label expansion of the drug should drive sales further. However, overdependence on Livmarli for revenues is a concern.

AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why

by Zacks Equity Research

AN2 Therapeutics (ANTX) falls 66% in a month after terminating its mycobacterium avium complex lung disease study of epetraborole due to unsatisfactory efficacy results.

Kodiak (KOD) Q2 Loss Narrower Than Expected, Pipeline in Focus

by Zacks Equity Research

Kodiak (KOD) reports a narrower-than-expected loss for the second quarter of 2024. The company provides updates regarding its pipeline development plans.

Lexicon (LXRX) to Reprioritize Portfolio, Slash Jobs, Stock Up

by Zacks Equity Research

Lexicon (LXRX) announces a portfolio reprioritization plan to focus on reducing operational expenses and driving the growth of the commercial portfolio. Shares rise.

Ascendis (ASND) Up on FDA Nod for Hormone Therapy Yorvipath

by Zacks Equity Research

The FDA approves Ascendis' (ASND) Yorvipath (palopegteriparatide) as the first and only treatment for hypoparathyroidism in adult patients. Shares rise.

Understanding Illumina (ILMN) Reliance on International Revenue

by Zacks Equity Research

Evaluate Illumina's (ILMN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Illumina (ILMN) Beats on Q2 Earnings, Lowers 2024 Sales View

by Zacks Equity Research

Illumina's (ILMN) Q2 earnings and revenues surpass estimates in a challenging global macroeconomic environment.

Compared to Estimates, Illumina (ILMN) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Illumina (ILMN) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Illumina (ILMN) delivered earnings and revenue surprises of 200% and 1.31%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Product Demand Likely to Aid Organon's (OGN) Q2 Earnings

by Zacks Equity Research

Continued solid uptake of Organon's (OGN) products is expected to have driven second-quarter revenues.

Nalak Das headshot

Buy 2 Biotech Bigwigs Set to Gain on Possible Earnings Beat

by Nalak Das

Two biotech bigwigs set to beat on earnings next week are: ILMN, GMAB.

Will HOOKIPA Pharma Inc. (HOOK) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

HOOKIPA Pharma (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Stay Ahead of the Game With Illumina (ILMN) Q2 Earnings: Wall Street's Insights on Key Metrics

by Zacks Equity Research

Get a deeper insight into the potential performance of Illumina (ILMN) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Illumina (ILMN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Why Illumina (ILMN) Could Beat Earnings Estimates Again

by Zacks Equity Research

Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Wall Street Analysts Think Illumina (ILMN) Could Surge 27.02%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 27% upside potential for Illumina (ILMN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Illumina (ILMN) Upgraded to Buy: Here's Why

by Zacks Equity Research

Illumina (ILMN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Illumina (ILMN) Buys Fluent, Grows in Single Cell Research

by Zacks Equity Research

By integrating Fluent's unique technology with Illumina's (ILMN) sequencing and informatics solutions, researchers are likely to gain access to a comprehensive solution for single-cell multiomic analysis.

Illumina (ILMN) Rises on Conclusion of GRAIL Divestment

by Zacks Equity Research

With the divestment now over, we expect Illumina (ILMN) to soar again on the assumption that the company will start to focus on its legacy businesses.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.